However, with only eight EGFR-mutated patients and the small number of patients with PD-L1 testing (13.4%), this precluded meaningful sensitivity analysis, introducing selection bias that may not reflect the broader population of stage III NSCLC patients receiving durvalumab consolidation. Here, EGFR is linked to non-small cell lung carcinoma.